COLOPLAST A/S-SPONSORED ADR Business Summary

Coloplast A/S (CLPBY) operates a high-margin medical device business model focused on the development, manufacture, and global distribution of intimate healthcare products. The company generates revenue primarily through direct sales and reimbursement-driven transactions across five core business segments: Ostomy Care, Continence Care, Interventional Urology, Wound & Tissue Repair (including the Kerecis fish-skin technology), and Voice & Respiratory Care. As of mid-2026, the company continues to execute its "Impact4" strategy, aiming for 7-8% organic growth by 2030 while navigating U.S. Medicare reimbursement shifts in its skin substitute division. Coloplast maintains a dominant market position as the global leader in ostomy and continence care, characterized by a wide economic moat and high switching costs. Its primary direct competitors include Convatec Group PLC, Hollister Incorporated, B. Braun SE, and Solventum, against whom Coloplast differentiates itself through specialized innovation and a superior market share in the European and emerging markets. Originally founded in 1957 by nurse Elise Sørensen and engineer Aage Louis-Hansen, the company is currently led by President and CEO Gavin Wood, who assumed the role on May 1, 2026. Wood brings over two decades of MedTech experience, previously serving as Company Group Chairman of Johnson & Johnson MedTech EMEA and Worldwide President of Ethicon Wound Closure & Healing. He is supported by long-standing CFO and Executive Vice President Anders Lonning-Skovgaard, who has overseen the company’s financial strategy since 2014. The leadership team was further bolstered in early 2026 by the appointment of Kevin Hardage as EVP of Interventional Urology, formerly of Teleflex. Governance is overseen by Interim Chairwoman Jette Nygaard-Andersen, with LEGO Group CEO Niels B. Christiansen serving as a key board member and designated future Chair. The company remains anchored by the Louis-Hansen family through Aage og Johanne Louis-Hansens Fond, ensuring long-term strategic stability.